Stable crystal of 4-oxoquinoline compound
Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractmetry.
1. A crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2θ of 6.56°, 13.20°, 19.86°, 20.84°, 21.22°, 25.22° as measured by X-ray powder diffractometer.
2. A crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2θ of 8.54°, 14.02°, 15.68°, 17.06°, 17.24°, 24.16°, 25.74° as measured by X-ray powder diffractometer.
3. A crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an extrapolated onset temperature of 162.1±5.0° C.
4. A pharmaceutical composition comprising the crystal of any one of claims 1 - 3 , and a pharmaceutically acceptable carrier, wherein said carrier is not a liquid carrier.
5. The pharmaceutical composition of claim 4 wherein the composition is in the form of a tablet, pill, powder or granule.
6. The pharmaceutical composition of claim 5 wherein the composition is in the form of a tablet.
7. A method of inhibiting integrase comprising administering to a mammal an integrase-inhibiting amount of the crystal of any one of claims 1 - 3 .
8. A method of treating a viral infection comprising administering to a mammal an anti-viral amount of the crystal of any one of claims 1 - 3 .
9. A method for the treatment of an HIV infection comprising administering to an HIV-infected mammal an effective amount of the crystal of any one of claims 1 - 3 .
10. An anti-HIV composition comprising the crystal of any one of claims 1 - 3 and one or more other anti-HIV active substances.
11. A method for the treatment of an HIV infection comprising administering to an HIV-infected mammal an effective amount of the crystal of any one of claims 1 - 3 and one or more other anti-HIV active substances.
12. The method of claim 7 wherein the mammal is a human.
13. The method of claim 8 wherein the mammal is a human.
14. The method of claim 9 wherein the mammal is a human.
15. The method of claim 11 wherein the mammal is a human.